Literature DB >> 31167767

Cascade of immunologic adverse events related to pembrolizumab treatment.

Arnaud Dhenin1, Vassiliki Samartzi2, Sarah Lejeune1, Emmanuel Seront1.   

Abstract

Immune checkpoint inhibitors, such as pembrolizumab, have significantly improved cancer patient outcome. Toxicities are usually moderate and manageable. However, some adverse events, if not early recognised, could be life-threatening. We report a patient with non-small cell lung cancer who received treatment with pembrolizumab and developed multiple immune-related adverse events both during and after completing treatment, including rash, pericarditis, colitis and myasthenia gravis. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gastrointestinal system; immunological products and vaccines; lung cancer (oncology); neuromuscular disease; pericardial disease

Mesh：

Substances：

Year:  2019        PMID： 31167767      PMCID： PMC6557364          DOI： 10.1136/bcr-2018-229149

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  26 in total

1.  Pembrolizumab-induced myasthenia gravis: A fatal case report.

Authors:  Katherine L March; Michael J Samarin; Amik Sodhi; Ryan E Owens
Journal:  J Oncol Pharm Pract       Date:  2017-02-01       Impact factor: 1.809

2.  A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma.

Authors:  Iyad Alnahhas; Jason Wong
Journal:  Muscle Nerve       Date:  2017-03-23       Impact factor: 3.217

Review 3.  Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

Authors:  Abhisek Swaika; William A Hammond; Richard W Joseph
Journal:  Mol Immunol       Date:  2015-03-05       Impact factor: 4.407

4.  Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

Authors:  Lisa Zimmer; Simone M Goldinger; Lars Hofmann; Carmen Loquai; Selma Ugurel; Ioannis Thomas; Maria I Schmidgen; Ralf Gutzmer; Jochen S Utikal; Daniela Göppner; Jessica C Hassel; Friedegund Meier; Julia K Tietze; Andrea Forschner; Carsten Weishaupt; Martin Leverkus; Renate Wahl; Ursula Dietrich; Claus Garbe; Michael C Kirchberger; Thomas Eigentler; Carola Berking; Anja Gesierich; Angela M Krackhardt; Dirk Schadendorf; Gerold Schuler; Reinhard Dummer; Lucie M Heinzerling
Journal:  Eur J Cancer       Date:  2016-04-13       Impact factor: 9.162

Review 5.  Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

Authors:  S Champiat; O Lambotte; E Barreau; R Belkhir; A Berdelou; F Carbonnel; C Cauquil; P Chanson; M Collins; A Durrbach; S Ederhy; S Feuillet; H François; J Lazarovici; J Le Pavec; E De Martin; C Mateus; J-M Michot; D Samuel; J-C Soria; C Robert; A Eggermont; A Marabelle
Journal:  Ann Oncol       Date:  2015-12-28       Impact factor: 32.976

6.  Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer.

Authors:  So Young Huh; Seong Hoon Shin; Meyung Kug Kim; So Young Lee; Ki Hun Son; Ha Young Shin
Journal:  J Clin Neurol       Date:  2018-01       Impact factor: 3.077

7.  Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer.

Authors:  Makoto Hibino; Kazunari Maeda; Shigeto Horiuchi; Minoru Fukuda; Tetsuri Kondo
Journal:  Respirol Case Rep       Date:  2018-08-07

8.  Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.

Authors:  Ahmad A Tarhini; Haris Zahoor; Yan Lin; Usha Malhotra; Cindy Sander; Lisa H Butterfield; John M Kirkwood
Journal:  J Immunother Cancer       Date:  2015-09-15       Impact factor: 13.751

Review 9.  Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

Authors:  Marnix H Geukes Foppen; Elisa A Rozeman; Sandra van Wilpe; Cindy Postma; Petur Snaebjornsson; Johannes V van Thienen; Monique E van Leerdam; Michel van den Heuvel; Christian U Blank; Jolanda van Dieren; John B A G Haanen
Journal:  ESMO Open       Date:  2018-01-13

Review 10.  Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

Authors:  Shrujal Baxi; Annie Yang; Renee L Gennarelli; Niloufer Khan; Ziwei Wang; Lindsay Boyce; Deborah Korenstein
Journal:  BMJ       Date:  2018-03-14
View more
  5 in total

1.  Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Authors:  Alessandro Inno; Nicola Maurea; Giulio Metro; Andreina Carbone; Antonio Russo; Stefania Gori
Journal:  Cancer Immunol Immunother       Date:  2021-04-20       Impact factor: 6.968

Review 2.  Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.

Authors:  Yu-Wen Zhou; Ya-Juan Zhu; Man-Ni Wang; Yao Xie; Chao-Yue Chen; Tao Zhang; Fan Xia; Zhen-Yu Ding; Ji-Yan Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

Review 3.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

Review 4.  Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.

Authors:  Liansha Tang; Jialing Wang; Nan Lin; Yuwen Zhou; Wenbo He; Jiyan Liu; Xuelei Ma
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

Review 5.  Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Lin Zhou; Xin Wei
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.